Zymeworks Inc. (NYSE:ZYME) Given Average Recommendation of “Moderate Buy” by Analysts

Zymeworks Inc. (NYSE:ZYMEGet Rating) has earned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $15.00.

Several research firms have recently commented on ZYME. Citigroup cut their price objective on Zymeworks from $27.00 to $21.00 in a report on Wednesday, September 14th. Wells Fargo & Company dropped their price target on Zymeworks from $45.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 4th. SVB Leerink cut Zymeworks from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $19.00 to $8.00 in a research note on Friday, October 21st. HC Wainwright cut Zymeworks from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $40.00 to $8.00 in a research report on Tuesday, November 1st. Finally, Stifel Nicolaus decreased their price target on Zymeworks from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, October 24th.

Zymeworks Trading Down 3.1 %

NYSE ZYME opened at $7.76 on Friday. The company has a market cap of $488.88 million, a PE ratio of -2.03 and a beta of 1.12. Zymeworks has a 12 month low of $4.11 and a 12 month high of $21.44. The stock has a 50 day moving average of $6.34 and a 200-day moving average of $6.22.

Zymeworks (NYSE:ZYMEGet Rating) last released its quarterly earnings data on Tuesday, November 8th. The company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.22. The company had revenue of $2.63 million during the quarter, compared to the consensus estimate of $4.74 million. Zymeworks had a negative return on equity of 89.24% and a negative net margin of 751.00%. As a group, sell-side analysts predict that Zymeworks will post -3.87 EPS for the current fiscal year.

Institutional Trading of Zymeworks

Several large investors have recently bought and sold shares of the business. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Zymeworks during the first quarter valued at about $31,000. Quantbot Technologies LP acquired a new position in shares of Zymeworks in the first quarter worth approximately $42,000. Envestnet Asset Management Inc. bought a new stake in Zymeworks in the second quarter worth approximately $62,000. First Republic Investment Management Inc. bought a new stake in Zymeworks in the first quarter worth approximately $66,000. Finally, Lazard Asset Management LLC bought a new stake in Zymeworks in the first quarter worth approximately $66,000. 92.45% of the stock is owned by institutional investors and hedge funds.

Zymeworks Company Profile

(Get Rating)

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

Featured Stories

Analyst Recommendations for Zymeworks (NYSE:ZYME)

Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.